Kolon TissueGene, Inc.

KOSDAQ:A950160 Stock Report

Market Cap: ₩2.3t

Kolon TissueGene Management

Management criteria checks 3/4

Kolon TissueGene's CEO is Moon-jong Noh, appointed in Jan 2019, has a tenure of 6.08 years. total yearly compensation is ₩548.27K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 0.06% of the company’s shares, worth ₩1.38B. The average tenure of the management team and the board of directors is 4.9 years and 5.1 years respectively.

Key information

Moon-jong Noh

Chief executive officer

₩548.3k

Total compensation

CEO salary percentage100.0%
CEO tenure6.1yrs
CEO ownership0.06%
Management average tenure4.9yrs
Board average tenure5.1yrs

Recent management updates

Recent updates


CEO

Moon-jong Noh (56 yo)

6.1yrs

Tenure

₩548,272

Compensation

Dr. Moon J. Noh, PhD, has been the Chief Executive Officer, President and Director of Kolon TissueGene, Inc. since 2019 and served as its Chief Technology Officer since June 6, 2017 until 2019 and served a...


Leadership Team

NamePositionTenureCompensationOwnership
Moon-jong Noh
CEO, President & Director6.1yrs₩548.27k0.060%
₩ 1.4b
Jung In Kim
CFO & Director3.2yrsno data0.000010%
₩ 228.3k
Sean Woo
VP of Business Development & General Counsel15.1yrsno datano data
Sun Jin Kim
Chief Medical Officer3.7yrsno datano data
Young J. Kim
Statutory Auditor & Directorno datano datano data

4.9yrs

Average Tenure

59yo

Average Age

Experienced Management: A950160's management team is considered experienced (4.9 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Moon-jong Noh
CEO, President & Director6.1yrs₩548.27k0.060%
₩ 1.4b
Jung In Kim
CFO & Director3.1yrsno data0.000010%
₩ 228.3k
Young J. Kim
Statutory Auditor & Director4.1yrsno datano data
Peter Shin
Member of Business Advisory Boardno datano datano data
Terry Lierman
Member of Business Advisory Boardno datano datano data
Michael Mont
Member of Clinical Advisory Boardno datano datano data
Philip Conaghan
Member of Scientific Advisory Board8.1yrsno datano data
Javad Parvizi
Member of Clinical Advisory Boardno datano datano data
David Hunter
Member of Scientific Advisory Board8.7yrsno datano data
Ali Mobasheri
Member of the Scientific Advisory Board5.1yrsno datano data
SunJoo Lee
Independent Outside Director1.8yrsno datano data

5.1yrs

Average Tenure

57yo

Average Age

Experienced Board: A950160's board of directors are considered experienced (5.1 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/01 20:53
End of Day Share Price 2025/01/31 00:00
EarningsN/A
Annual EarningsN/A

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Kolon TissueGene, Inc. is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Hye Min HuhiM Securities
Wan KuNH Investment & Securities Co., Ltd.